Recombinant Human Matriptase/ST14 Catalytic Domain, CF | R&D Systems 3946-SEB-010 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human Matriptase/ST14 Catalytic Domain, CF

catalog :

3946-SEB-010

quantity :

10 ug

price :

502 USD

citations: 18

Reference
Peng T, Wen J, Huang G, Zhao H, Liu J. First-generation high-affinity ST14 radiopharmaceutical: Design, synthesis, and preclinical PET imaging evaluation for pancreatic cancer detection. Bioorg Chem. 2025;154:108085 pubmed publisher
W xf3 jcik Mieszawska S, Lewtak K, Skwarek E, D x119 bowski D, Gitlin Domagalska A, Nowak J, et al. Autophagy of Candida albicans cells after the action of earthworm Venetin-1 nanoparticle with protease inhibitor activity. Sci Rep. 2023;13:14228 pubmed publisher
Yang J, Tong C, Qi J, Liao X, Li X, Zhang X, et al. Engineering and Structural Insights of a Novel BBI-like Protease Inhibitor Livisin from the Frog Skin Secretion. Toxins (Basel). 2022;14: pubmed publisher
Kalogera S, He Y, Bay Jensen A, Gantzel T, Sun S, Manon Jensen T, et al. The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment. Sci Rep. 2021;11:24285 pubmed publisher
Howng B, Winter M, LePage C, Popova I, Krimm M, Vasiljeva O. Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies. Pharmaceutics. 2021;13: pubmed publisher
Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, et al. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics. 2021;13: pubmed publisher
Iyer A, Humphries T, Owens E, Zhao K, Masci P, Johnson D, et al. PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. Front Physiol. 2021;12:615428 pubmed publisher
Geiger M, Stubenrauch K, Sam J, Richter W, Jordan G, Eckmann J, et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat Commun. 2020;11:3196 pubmed publisher
Chen L, Chai K. Matriptase cleaves the amyloid-beta peptide 1-42 at Arg-5, Lys-16, and Lys-28. BMC Res Notes. 2019;12:5 pubmed publisher
Tamberg T, Hong Z, De Schepper D, Skovbjerg S, Dupont D, Vitved L, et al. Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors. J Biol Chem. 2019;294:314-326 pubmed publisher
Straus M, Whittaker G. A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site. PLoS ONE. 2017;12:e0174827 pubmed publisher
Ferguson T, Reihill J, Walker B, Hamilton R, Martin S. A Selective Irreversible Inhibitor of Furin Does Not Prevent Pseudomonas Aeruginosa Exotoxin A-Induced Airway Epithelial Cytotoxicity. PLoS ONE. 2016;11:e0159868 pubmed publisher
Wood M, Cole A, Eade C, Chen L, Chai K, Cole A. The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2. Immunology. 2014;142:474-83 pubmed publisher
Quimbar P, Malik U, Sommerhoff C, Kaas Q, Chan L, Huang Y, et al. High-affinity cyclic peptide matriptase inhibitors. J Biol Chem. 2013;288:13885-96 pubmed publisher
Tsujimoto H, Kotsyfakis M, Francischetti I, Eum J, Strand M, Champagne D. Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responses. PLoS ONE. 2012;7:e29964 pubmed publisher
Sales K, Masedunskas A, Bey A, Rasmussen A, Weigert R, List K, et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet. 2010;42:676-83 pubmed publisher
Clark E, Jovov B, Rooj A, Fuller C, Benos D. Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase. J Biol Chem. 2010;285:27130-43 pubmed publisher
Myerburg M, McKenna E, Luke C, Frizzell R, Kleyman T, Pilewski J. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L932-41 pubmed publisher

product information

master code :

3946-SEB

SKU :

3946-SEB-010

product name :

Recombinant Human Matriptase/ST14 Catalytic Domain, CF

unit size :

10 ug

description :

The Recombinant Human Matriptase/ST14 Catalytic Domain, CF from R&D Systems is derived from E. coli. The Recombinant Human Matriptase/ST14 Catalytic Domain, CF has been validated for the following applications: Enzyme Activity.

target :

Matriptase/ST14

category :

Proteins and Enzymes

buffer :

Supplied as a 0.2 ╡m filtered solution in Tris-HCl and Glycerol.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

27 kDa (major) and minor auto-activation fragments, reducing conditions

theoretical molecular weight :

26 kDa

details of functionality :

Measured by its ability to cleave the fluorogenic peptide substrate Boc-QAR-AMC (Catalog # ES014 ). The specific activity is 10,000 pmol/min/╡g, as measured under the described conditions.

endotoxin note :

<1.0 EU per 1 ╡g of the protein by the LAL method.

top caption :

Recombinant Human Matriptase/ST14 Catalytic Domain Enzyme Activity

accessionNumbers :

NP_068813

applications :

Enzyme Activity

source long :

E. coli -derived human Matriptase/ST14 protein Gly596-Val855, with an N-terminal Met and 6-His tag The protein was purified, auto-activated and further purified.

source short :

E. coli

USD :

502 USD

alt names :

EC 3.4.21, Epithin, HAI, Matriptase, Membrane-type serine protease 1, MTSP1, MT-SP1EC 3.4.21.109, prostamin, PRSS14, Serine protease 14, Serine protease TADG-15, SNC19, SNC19MTSP1, ST14, suppression of tumorigenicity 14 (colon carcinoma), suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin), suppressor of tumorigenicity 14 protein, TADG15, TADG-15, TMPRSS14, tumor associated differentially expressed gene 15 protein, Tumor-associated differentially-expressed gene 15 protein

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 ░C as supplied. 3 months, -20 to -70 ░C under sterile conditions after opening.